COMPANY PROFILE

Inocras

Explore full profile

Providing a comprehensive view of a patient's entire genetic profile through WGS analysis and interpretations

San Diego, United StatesFounded 2020Biotech & Life Sciences

Valuation $100–250M Last recorded · 2025

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Inocras

Inocras is an AI-driven company that specializes in delivering critical insights to cancer and rare disease patients through whole genome sequencing and bioinformatics. The company offers its whole genome testing products, CancerVision, RareVision and MRDVision, and provides research services for pharmaceutical and biotechnology companies as well as research organizations through its CAP/CLIA lab, powered by its proprietary, IP-protected bioinformatics pipeline. Inocras is dedicated to unlocking the potential of whole genome data to enable precision health for everyone.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2020
Headquarters: San Diego, United States
Employees: 74
Open positions: None listed
Dealroom signal: 63.2/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, DNA, Genetics and genomics, Precision Medicine, Disease, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

5 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VCOther financing	Jul 2025	$12M	$210M	Premier Partners · Forest Partners	—
SERIES BOther financing	Nov 2023	$23M	$190M	SIGNITE PARTNERS · Big Move Ventures · Samsung Ventures · DSC Investment	↗

Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Inocras website traffic

Latest recorded traffic for Inocras is 11K monthly website visits, down 26.7% over the last three months. Inocras's team grew 8.8% over the past year.

Latest monthly visits11K 3-month web change-26.7% 1-year team growth+8.8%

Monthly website visitsJul 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
DLDante LabsDante Labs is transforming genetics	New York City, United States	Operational	124	—	—
GEGeneYouInGeneYouIn (GYI), a Canadian personalized medicine company, has developed a genome analytics and reporting platform called PillCheck	Toronto, Canada	Operational
BABasgenbioVaszenio is a bio-vitator based on artificial intelligence that offers more than health value	Seoul, South Korea	Operational
NTNucleome TherapeuticsDecoding the dark matter of the human genome to discover first-in-class precision medicine	Oxford, United Kingdom	Operational
PBPencil BiosciencesPencil Biosciences is a novel gene modulation company	Alderley Edge, United Kingdom	Operational
SOSolveBioSolveBio deploys technology and on-demand expertise to drive precision medicine We monitor, gather, and secure Genomic Intelligence	New York City, United States	Acquired
ACActXFocused on making patient genomic information that are useful in everyday medical practice	Seattle, United States	Operational
LILifebitEmpowers therapeutic leaders and pioneers in precision medicine on how to access and analyse siloed biomedical data	London, United Kingdom	Operational